Studybox Research Dual Submission Studies
Point-of-Care Pregnancy (hCG) Test
One integrated study supporting both 510(k) clearance and CLIA waiver.
Studybox
Dual Submission Studies
Urine hCG testing is one of the original CLIA-waived tests, and professional and consumer versions have been cleared for decades. The clinical study compares the qualitative device to a quantitative laboratory hCG assay, with specimens concentrated near the device's claimed detection limit, and establishes clinical performance against confirmed pregnancy outcome. Early pregnancy specimens are the hard part: the study needs women tested in the days around expected menses, when hCG is low and rising, which requires targeted recruitment through fertility care or prospective cycle tracking.
Two analytical issues recur. Urine hCG is partly present as the beta core fragment, which some antibody pairs detect poorly and which can cause false negatives in some urine specimens; and very high hCG concentrations can produce a hook effect in some device formats. Point-of-care devices with a whole blood claim add a specimen type with its own matrix questions, often for emergency department use before imaging or medication.
- Analyte
- Human chorionic gonadotropin (hCG), qualitative
- Therapeutic area
- Women's Health
- Specimens
- Urine, Serum and Plasma, Venous Whole Blood
- Intended-use settings
- physician office, urgent care, emergency department, pharmacy, home use
- Operators
- Non-laboratory clinic staff in waived settings; lay users for over-the-counter versions.
- Comparator
- Typically a quantitative laboratory serum hCG immunoassay, with pregnancy status confirmed by clinical follow-up where the protocol requires it.
Dual Submission specifics
What Changes for This Assay on This Pathway.
- A single study at waived sites with untrained operators and a quantitative laboratory hCG comparator on paired serum supports both components for urine; additional specimen types are typically supported by laboratory comparisons.
- Over-the-counter versions add a lay user arm in which consumers test their own urine and interpret results, along with labeling comprehension.
- Early pregnancy recruitment (fertility clinics, prospective tracking of women seeking pregnancy) is typically arranged alongside the waived-setting sites, which see mostly later or established pregnancies.
Endpoints the study must support
- Agreement with the quantitative hCG comparator classified at the device's claimed detection limit, with separate reporting of specimens near the limit
- Clinical sensitivity and specificity against confirmed pregnancy status, including early pregnancy around the time of expected menses
- Agreement across claimed specimen types (urine, serum, plasma, whole blood)
- For over-the-counter claims, lay user agreement and interpretation of results
Enrollment realities
Driven by early pregnancy specimens near the detection limit, which are uncommon in general clinic populations; fertility and prospective-cycle recruitment supply them. Negative and strongly positive specimens accrue quickly.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run dual submission studies →
Same assay, other pathways
Relevant FDA guidance
FAQ
Point-of-Care Pregnancy (hCG) Test Study Questions.
01 Who operates the point-of-care pregnancy (hcg) test in a dual submission study?
Non-laboratory clinic staff in waived settings; lay users for over-the-counter versions.
02 What is the comparator for a point-of-care pregnancy (hcg) test study?
Typically a quantitative laboratory serum hCG immunoassay, with pregnancy status confirmed by clinical follow-up where the protocol requires it.
03 What drives enrollment for a point-of-care pregnancy (hcg) test study?
Driven by early pregnancy specimens near the detection limit, which are uncommon in general clinic populations; fertility and prospective-cycle recruitment supply them. Negative and strongly positive specimens accrue quickly.
Let's talk IVD research
Planning a point-of-care pregnancy (hcg) test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the dual submission pathway.